Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04899349
Title Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

breast cancer

Therapies

Alpelisib + Fulvestrant + Metformin

Alpelisib + Dapagliflozin + Fulvestrant + Metformin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST